(redirected from Acid Control)
Also found in: Dictionary, Thesaurus.


an antagonist of histamine H2receptors, inhibiting the action of histamine at cell surface receptors of the gastric parietal cells and reducing basal gastric acid secretion and secretion stimulated by food, histamine, gastrin, caffeine, and insulin. It is administered orally for the short-term (two months) treatment and, at reduced dosage, the long term prevention, of peptic ulcers, for the relief of symptoms associated with hyperacidity, such as heartburn and acid indigestion, and for the treatment of gastroesophageal reflux disease, upper gastrointestinal bleeding, and pathological hypersecretory conditions such as zollinger-ellison syndrome.


Apo-Famotidine (CA), Gen-Famotidine (CA), Maalox H2 Acid Controller, Mylanta AR, Novo-Famotidine (CA), Nu-Famotidine (CA), Pepcid, Pepcid AC, Ulcidine (CA), Ultra Heartburn Relief (UK)

Pharmacologic class: Histamine2-receptor antagonist

Therapeutic class: Antiulcer drug

Pregnancy risk category B


Blocks action of histamine at histamine2-receptor sites in gastric parietal cells, inhibiting gastric acid secretion and stabilizing pepsin


Gelcaps: 10 mg

Oral suspension: 40 mg/5 ml

Solution for injection: 10 mg/ml, 20 mg/50 ml of normal saline solution

Tablets: 10 mg, 20 mg, 40 mg

Tablets (chewable): 10 mg

Tablets (orally disintegrating): 20 mg, 40 mg

Indications and dosages

Active duodenal ulcers and benign gastric ulcers

Adults: 40 mg P.O. once daily at bedtime or 20 mg P.O. b.i.d. for up to 8 weeks

Prophylaxis of duodenal ulcers

Adults: 20 mg P.O. once daily at bedtime

Gastroesophageal reflux disease

Adults: 20 mg P.O. b.i.d. for up to 6 weeks. Maximum dosage is 40 mg b.i.d. for up to 12 weeks.

Children ages 1 to 16: 1 mg/kg P.O. daily in two divided doses, to a maximum of 40 mg b.i.d.

Infants ages 3 months to 1 year: 0.5 mg/kg P.O. b.i.d. for up to 8 weeks

Infants younger than age 3 months: 0.5 mg/kg P.O. once daily for up to 8 weeks

Gastric hypersecretory conditions (such as Zollinger-Ellison syndrome)

Adults: Initially, 20 mg P.O. q 6 hours, increased as needed to 160 mg q 6 hours

Hospitalized patients with pathologic hypersecretory conditions or ulcers; patients who can't take oral drugs

Adults: 20 mg I.V. q 12 hours

Prevention or treatment of heartburn, acid indigestion, and sour stomach (Pepcid AC only)

Adults: For prevention, 10 mg P.O. 1 hour before eating, or 10-mg chewable tablet 15 minutes before eating, to a maximum of 20 mg/24 hours for up to 2 weeks. For symptomatic treatment, 10 mg P.O. once or twice daily.

Dosage adjustment

• Renal impairment


• Hypersensitivity to drug or other histamine2-receptor antagonists


Use cautiously in:

• renal impairment with prolonged QT interval and seizures (very rare)

• elderly patients

• pregnant or breastfeeding patients.


• Be aware that drug usually is given in one daily dose to patients with renal insufficiency.

• Give P.O. form with foods or liquids.

• Dilute I.V. form with 10 ml dextrose 5% in water or normal saline solution (100 ml) for I.V. piggyback administration.

• Deliver by I.V. push over 2 minutes or intermittent infusion over 30 minutes.

• Know that drug may cause transient irritation at I.V. site.

Adverse reactions

CNS: dizziness, headache, paresthesia, asthenia, fatigue, insomnia, somnolence, psychic disturbances

CV: palpitations, arrhythmias, AV block

GI: nausea, vomiting, diarrhea, constipation, dry mouth, anorexia, cholestatic jaundice, abdominal pain

GU: decreased libido

Hematologic: agranulocytosis, pancytopenia, leukopenia, thrombocytopenia (rare)

Hepatic: liver enzyme abnormalities, hepatitis

EENT: orbital edema, conjunctival redness, tinnitus

Musculoskeletal: musculoskeletal pain, muscle cramps, arthralgia

Respiratory: bronchospasm, interstitial pneumonia

Skin: flushing, acne, dry skin, rash, urticaria, alopecia, pruritus; epidermal necrolysis and Stevens-Johnson syndrome (very rare)

Other: altered taste, fever, pain at injection site, hypersensitivity reactions including anaphylaxis and angioedema


Drug-diagnostic tests. Liver enzymes: altered levels

Patient monitoring

• Assess patient for GI signs and symptoms.

• Monitor blood urea nitrogen and creatinine levels in patients with renal impairment.

Monitor patient for prolonged QT interval and seizures, which have been reported very rarely in patients with impaired renal function whose famotidine dosage or dosing interval may not have been adjusted appropriately. Also monitor patient for arrhythmia and AV block.

Monitor patient for signs and symptoms of epidermal necrolysis, Stevens-Johnson syndrome, and hematologic or respiratory changes.

Patient teaching

• Tell patient that drug is most effective when taken at bedtime.

• Inform patient that pain relief may not begin until several days after therapy starts.

Instruct patient to take drug exactly as prescribed and to immediately report cardiovascular signs and symptoms, seizures, and hematologic or respiratory changes.

• Tell female patient to inform prescriber if she is pregnant or breastfeeding.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


/fam·o·ti·dine/ (fam-o´tĭ-dēn) a histamine H2 receptor antagonist, which inhibits gastric acid secretion; used in the treatment and prophylaxis of gastric or duodenal ulcers, gastroesophageal reflux disease, upper gastrointestinal bleeding, and conditions associated with gastric hypersecretion.


A histamine antagonist, C8H15N7O2S3, that inhibits the secretion of gastric acid and is used to treat duodenal and gastric ulcers and gastroesophageal reflux disease.


an oral and parenteral antiulcer drug; an H2-receptor antagonist.
indications It is prescribed in treatment of duodenal ulcer and pathological hypersecretory conditions, and for stress-ulcer prophylaxis.
contraindications Famotidine should be used with caution in patients with impaired kidney function.
adverse effects Among adverse effects reported are headache, dizziness, constipation, diarrhea, and temporary irritation of the injection site.


Pepcid Therapeutics An agent used to treat peptic ulcer disease by blocking binding of histamine to H2 receptors, resulting in ↓ intracellular concentration of cAMP and acid secretion by gastric parietal cells Adverse reactions Diarrhea, headache, drowsiness, fatigue, muscle pain, constipation, rarely, also mental confusion, agranulocytosis, gynecomastia, impotence, allergic reactions, myalgias, tachycardia, arrhythmias, interstitial nephritis, etc. See Histamine receptor antagonist.


An H2 RECEPTOR ANTAGONIST drug used to treat peptic ulcers and reflux oesophagitis (heartburn). A brand name is Pepsid.


n brand names: Pepcid, Pepcid IV;
drug class: H2-histamine receptor antagonist;
action: inhibits histamine at H2 receptor site in parietal cells, which inhibits gastric acid secretion;
uses: short-term treatment of active duodenal ulcer, gastric ulcer, and heartburn.


a histamine H2-receptor antagonist, similar to cimetidine.
References in periodicals archive ?
Many hope that Sharmeen Obaid-Chinoy's Oscar winning film, "Saving Face," exploring acid-attacks, will bring the much needed pressure to transform the Acid Control and Acid Crime Prevention Bill into action.
crime; Acid Control and Acid Crime Prevention Act; Women in Distress and Detention Fund Act; Social protection and safety nets, insurance and microfinance schemes, and the Benazir Income Support Programme;
In 2011, Pakistan introduced the Acid Control and Acid Crime Bill that recommends a 14- year imprisonment and 1 million Pakistani rupees as fine for acid attackers.
Claiming that the government's highest priority is to address discriminatory laws against women, the president listed down the legislative measures taken to protect women, which included Adoption of Protection against Harassment of Women at Workplace Act 2010, Criminal Law (Amendment) Act, Acid Control and Acid Crime Act and Prevention of Anti Women Practices Act.
Memon and her colleagues, Shahnaz Sheikh and Anusha Rehman, proposed the Acid Control and Acid Crime Prevention Bill 2011, which recommends 14 years to a lifetime in prison and a Rs1m fine.
This is the first reported incident of acid-throwing since parliament passed the 2010 Acid Control and Prevention Bill to declare the act a crime against women and prescribing harsh penalties against such acts.
s Zegerid (omeprazole/ sodium bicarbonate) capsules, an immediate-release oral proton pump inhibitor providing continued acid control for patients with gastroesophagael reflux disease (GERD).
0 mM, but a weak acid control benzoic acid was ineffective.
Of the OTC remedy users, 87% take an antacid; that's suboptimal because antacids provide rapid but only brief acid control.
BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds while rheumatologists and primary care physicians (PCPs) in the United States recognize the importance of tight uric acid control as a strategy to minimize gout flares, the majority of gout patients have serum uric acid (SUA) levels above the therapeutic target of 6.
Criminal Law (Second Amendment) Act, 2011 known as Acid Control and Acid was enacted on December 28, 2011 to provide protection to women against defacing through acid throwing.
Some landmark legislation through political consensus included the Bill on Acid Control and Acid Crime Prevention - passed unanimously on May 10, 2011.